European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy

Thomas Powles; Michael Staehler; Börje Ljungberg; Karim Bensalah; Steven E Canfield; Saeed Dabestani; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Alessandro Volpe; Axel Bex

doi:10.1016/j.eururo.2016.06.009

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy

Eur Urol. 2016 Nov;70(5):705-706. doi: 10.1016/j.eururo.2016.06.009. Epub 2016 Jun 24.

Authors

Thomas Powles¹, Michael Staehler², Börje Ljungberg³, Karim Bensalah⁴, Steven E Canfield⁵, Saeed Dabestani⁶, Rachel H Giles⁷, Fabian Hofmann⁸, Milan Hora⁹, Markus A Kuczyk¹⁰, Thomas Lam¹¹, Lorenzo Marconi¹², Axel S Merseburger¹³, Alessandro Volpe¹⁴, Axel Bex¹⁵

Affiliations

¹ The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: Thomas.Powles@bartshealth.nhs.uk.
² Department of Urology, Ludwig-Maximilians University, Munich, Germany.
³ Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
⁴ Department of Urology, University of Rennes, Rennes, France.
⁵ Division of Urology, University of Texas Medical School at Houston, Houston, TX, USA.
⁶ Department of Urology, Skåne University Hospital, Malmö, Sweden.
⁷ Patient Advocate International Kidney Cancer Coalition (IKCC), University Medical Centre Utrecht, Nephrology Department, Utrecht, The Netherlands.
⁸ Department of Urology, Sunderby Hospital, Sunderby, Sweden.
⁹ Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
¹⁰ Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
¹¹ Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
¹² Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
¹³ Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
¹⁴ Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
¹⁵ Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

PMID: 27349614
DOI: 10.1016/j.eururo.2016.06.009

Abstract

The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

Keywords: Cabozantinib; European Association of Urology; Guidelines; Nivolumab; Renal cancer.

MeSH terms

Anilides / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Antineoplastic Agents / administration & dosage
Carcinoma, Renal Cell / drug therapy*
Humans
Nivolumab
Pyridines / administration & dosage*
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

Substances

Anilides
Antibodies, Monoclonal
Antineoplastic Agents
Pyridines
cabozantinib
Nivolumab
Receptors, Vascular Endothelial Growth Factor